Selected research
Industry Research
Respiratory Disease Vaccine Industry Research Report 2026
Market perspective
The global Respiratory Disease Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Respiratory Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Respiratory Disease Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Respiratory Disease Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Respiratory Disease Vaccine include Sanofi SA, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., SINOVAC, Serum Institute of India Pvt. Ltd., Novavax, GSK plc. and Emergent BioSolutions Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Respiratory Disease Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Respiratory Disease Vaccine Market by Company
Sanofi SA
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Pfizer Inc.
SINOVAC
Serum Institute of India Pvt. Ltd.
Novavax
GSK plc.
Emergent BioSolutions Inc.
AstraZeneca
Respiratory Disease Vaccine Segment by Type
Live Attenuated
Inactivated
Others
Respiratory Disease Vaccine Segment by Application
Flu
Pneumonia
Others
Respiratory Disease Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Disease Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Disease Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Disease Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Respiratory Disease Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Respiratory Disease Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Respiratory Disease Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Live Attenuated
- Inactivated
- Others
Applications
- Flu
- Pneumonia
- Others
Companies covered
- Sanofi SA
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- SINOVAC
- Serum Institute of India Pvt. Ltd.
- Novavax
- GSK plc.
- Emergent BioSolutions Inc.
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Respiratory Disease Vaccine Market Size (2021-2032)
- 2.2.2 Global Respiratory Disease Vaccine Sales (2021-2032)
- 2.2.3 Global Respiratory Disease Vaccine Market Average Price (2021-2032)
- 2.3 Respiratory Disease Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Live Attenuated
- 2.3.3 Inactivated
- 2.3.4 Others
- 2.4 Respiratory Disease Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Flu
- 2.4.3 Pneumonia
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Respiratory Disease Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Respiratory Disease Vaccine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Respiratory Disease Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Respiratory Disease Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Respiratory Disease Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Respiratory Disease Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Respiratory Disease Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Respiratory Disease Vaccine, Established Date
- 3.9 Global Respiratory Disease Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi SA
- 4.1.1 Sanofi SA Company Information
- 4.1.2 Sanofi SA Business Overview
- 4.1.3 Sanofi SA Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi SA Respiratory Disease Vaccine Product Portfolio
- 4.1.5 Sanofi SA Recent Developments
- 4.2 Johnson & Johnson Services, Inc.
- 4.2.1 Johnson & Johnson Services, Inc. Company Information
- 4.2.2 Johnson & Johnson Services, Inc. Business Overview
- 4.2.3 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Product Portfolio
- 4.2.5 Johnson & Johnson Services, Inc. Recent Developments
- 4.3 Merck & Co., Inc.
- 4.3.1 Merck & Co., Inc. Company Information
- 4.3.2 Merck & Co., Inc. Business Overview
- 4.3.3 Merck & Co., Inc. Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck & Co., Inc. Respiratory Disease Vaccine Product Portfolio
- 4.3.5 Merck & Co., Inc. Recent Developments
- 4.4 Pfizer Inc.
- 4.4.1 Pfizer Inc. Company Information
- 4.4.2 Pfizer Inc. Business Overview
- 4.4.3 Pfizer Inc. Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Inc. Respiratory Disease Vaccine Product Portfolio
- 4.4.5 Pfizer Inc. Recent Developments
- 4.5 SINOVAC
- 4.5.1 SINOVAC Company Information
- 4.5.2 SINOVAC Business Overview
- 4.5.3 SINOVAC Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 SINOVAC Respiratory Disease Vaccine Product Portfolio
- 4.5.5 SINOVAC Recent Developments
- 4.6 Serum Institute of India Pvt. Ltd.
- 4.6.1 Serum Institute of India Pvt. Ltd. Company Information
- 4.6.2 Serum Institute of India Pvt. Ltd. Business Overview
- 4.6.3 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Product Portfolio
- 4.6.5 Serum Institute of India Pvt. Ltd. Recent Developments
- 4.7 Novavax
- 4.7.1 Novavax Company Information
- 4.7.2 Novavax Business Overview
- 4.7.3 Novavax Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Novavax Respiratory Disease Vaccine Product Portfolio
- 4.7.5 Novavax Recent Developments
- 4.8 GSK plc.
- 4.8.1 GSK plc. Company Information
- 4.8.2 GSK plc. Business Overview
- 4.8.3 GSK plc. Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GSK plc. Respiratory Disease Vaccine Product Portfolio
- 4.8.5 GSK plc. Recent Developments
- 4.9 Emergent BioSolutions Inc.
- 4.9.1 Emergent BioSolutions Inc. Company Information
- 4.9.2 Emergent BioSolutions Inc. Business Overview
- 4.9.3 Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Emergent BioSolutions Inc. Respiratory Disease Vaccine Product Portfolio
- 4.9.5 Emergent BioSolutions Inc. Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca Respiratory Disease Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca Respiratory Disease Vaccine Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
5 Global Respiratory Disease Vaccine Market Scenario by Region
- 5.1 Global Respiratory Disease Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Respiratory Disease Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Respiratory Disease Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Respiratory Disease Vaccine Sales by Region: 2027-2032
- 5.3 Global Respiratory Disease Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Respiratory Disease Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Respiratory Disease Vaccine Revenue by Region: 2027-2032
- 5.4 North America Respiratory Disease Vaccine Market Facts & Figures by Country
- 5.4.1 North America Respiratory Disease Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Respiratory Disease Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Respiratory Disease Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Respiratory Disease Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Respiratory Disease Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Respiratory Disease Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Respiratory Disease Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Respiratory Disease Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Respiratory Disease Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Respiratory Disease Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Respiratory Disease Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Respiratory Disease Vaccine Market Facts & Figures by Country
- 5.7.1 South America Respiratory Disease Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Respiratory Disease Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Respiratory Disease Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Respiratory Disease Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Respiratory Disease Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Respiratory Disease Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Respiratory Disease Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Respiratory Disease Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Respiratory Disease Vaccine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Respiratory Disease Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Respiratory Disease Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Respiratory Disease Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Respiratory Disease Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Respiratory Disease Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Respiratory Disease Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Respiratory Disease Vaccine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Respiratory Disease Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Respiratory Disease Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Respiratory Disease Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Respiratory Disease Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Respiratory Disease Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Respiratory Disease Vaccine Value Chain Analysis
- 8.1.1 Respiratory Disease Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Respiratory Disease Vaccine Production Mode & Process
- 8.2 Respiratory Disease Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Respiratory Disease Vaccine Distributors
- 8.2.3 Respiratory Disease Vaccine Customers
9 Global Respiratory Disease Vaccine Analyzing Market Dynamics
- 9.1 Respiratory Disease Vaccine Industry Trends
- 9.2 Respiratory Disease Vaccine Industry Drivers
- 9.3 Respiratory Disease Vaccine Industry Opportunities and Challenges
- 9.4 Respiratory Disease Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst